{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T18:07:23Z","timestamp":1784311643461,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11523-019-00691-z","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:02:26Z","timestamp":1575849746000},"page":"67-73","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pemetrexed\/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Seung Tae","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Yong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Oh","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Young","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Ki","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Suk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,9]]},"reference":[{"key":"691_CR1","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1158\/1055-9965.EPI-10-0437","volume":"19","author":"A Jemal","year":"2010","unstructured":"Jemal A, Center MM, Desantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893\u2013907.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"691_CR2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0039-6109(02)00046-4","volume":"82","author":"ET Hawk","year":"2002","unstructured":"Hawk ET, Limburg PJ, Viner JL. Epidemiology and prevention of colorectal cancer. Surg Clin North Am. 2002;82:905\u201341.","journal-title":"Surg Clin North Am"},{"key":"691_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"JY Douillard","year":"2013","unstructured":"Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023\u201334.","journal-title":"N Engl J Med"},{"key":"691_CR4","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/S1470-2045(16)30269-8","volume":"17","author":"S Stintzing","year":"2016","unstructured":"Stintzing S, Modest DP, Rossius L, Lerch MM, Von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 2016;17:1426\u201334.","journal-title":"Lancet Oncol"},{"key":"691_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin"},{"key":"691_CR6","first-page":"1116","volume":"57","author":"C Shih","year":"1997","unstructured":"Shih C, Chen VJ, Gossett LS, Gates SB, Mackellar WC, Habeck LL, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57:1116\u201323.","journal-title":"Cancer Res"},{"key":"691_CR7","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1023\/A:1008372529239","volume":"10","author":"C Cripps","year":"1999","unstructured":"Cripps C, Burnell M, Jolivet J, Batist G, Lofters W, Dancey J, et al. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol. 1999;10:1175\u20139.","journal-title":"Ann Oncol"},{"key":"691_CR8","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1807::AID-CNCR8>3.0.CO;2-L","volume":"88","author":"W John","year":"2000","unstructured":"John W, Picus J, Blanke CD, Clark JW, Schulman LN, Rowinsky EK, et al. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer. 2000;88:1807\u201313.","journal-title":"Cancer"},{"key":"691_CR9","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.7150\/jca.24948","volume":"9","author":"SW Lim","year":"2018","unstructured":"Lim SW, Lee S, Lee J, Park SH, Park JO, Park YS, et al. Pemetrexed monotherapy as salvage treatment in patients with metastatic colorectal cancer refractory to standard chemotherapy: a phase II single-arm prospective trial. J Cancer. 2018;9:2910\u20135.","journal-title":"J Cancer"},{"key":"691_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","volume":"19","author":"DS Salomon","year":"1995","unstructured":"Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183\u2013232.","journal-title":"Crit Rev Oncol Hematol"},{"key":"691_CR11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1357-2725(99)00015-1","volume":"31","author":"A Wells","year":"1999","unstructured":"Wells A. EGF receptor. Int J Biochem Cell Biol. 1999;31:637\u201343.","journal-title":"Int J Biochem Cell Biol"},{"key":"691_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0163-7258(98)00045-X","volume":"82","author":"JR Woodburn","year":"1999","unstructured":"Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 1999;82:241\u201350.","journal-title":"Pharmacol Ther"},{"key":"691_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0093-7754(03)70011-6","volume":"30","author":"RW Akita","year":"2003","unstructured":"Akita RW, Sliwkowski MX. Preclinical studies with Erlotinib (Tarceva). Semin Oncol. 2003;30:15\u201324.","journal-title":"Semin Oncol"},{"key":"691_CR14","first-page":"4838","volume":"57","author":"JD Moyer","year":"1997","unstructured":"Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997;57:4838\u201348.","journal-title":"Cancer Res"},{"key":"691_CR15","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/annonc\/mdl481","volume":"18","author":"I Chau","year":"2007","unstructured":"Chau I, Cunningham D, Hickish T, Massey A, Higgins L, Osborne R, et al. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. Ann Oncol. 2007;18:730\u20137.","journal-title":"Ann Oncol"},{"key":"691_CR16","doi-asserted-by":"publisher","first-page":"9265","DOI":"10.1200\/JCO.2005.03.0536","volume":"23","author":"ML Rothenberg","year":"2005","unstructured":"Rothenberg ML, Lafleur B, Levy DE, Washington MK, Morgan-Meadows SL, Ramanathan RK, et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol. 2005;23:9265\u201374.","journal-title":"J Clin Oncol"},{"key":"691_CR17","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M","volume":"92","author":"NS Goldstein","year":"2001","unstructured":"Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer. 2001;92:1331\u201346.","journal-title":"Cancer"},{"key":"691_CR18","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/S0959-8049(02)00234-4","volume":"38","author":"JA Mckay","year":"2002","unstructured":"Mckay JA, Murray LJ, Curran S, Ross VG, Clark C, Murray GI, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer. 2002;38:2258\u201364.","journal-title":"Eur J Cancer"},{"key":"691_CR19","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1158\/1078-0432.CCR-03-0462","volume":"10","author":"MB Resnick","year":"2004","unstructured":"Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res. 2004;10:3069\u201375.","journal-title":"Clin Cancer Res"},{"key":"691_CR20","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1158\/1078-0432.CCR-06-2923","volume":"13","author":"T Li","year":"2007","unstructured":"Li T, Ling YH, Goldman ID, Perez-Soler R. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res. 2007;13:3413\u201322.","journal-title":"Clin Cancer Res"},{"key":"691_CR21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3892\/etm.2011.293","volume":"2","author":"L Wang","year":"2011","unstructured":"Wang L, Zhu ZX, Zhang WY, Zhang WM. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells. Exp Ther Med. 2011;2:969\u201375.","journal-title":"Exp Ther Med"},{"key":"691_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00428-006-0247-9","volume":"449","author":"F Bibeau","year":"2006","unstructured":"Bibeau F, Boissiere-Michot F, Sabourin JC, Gourgou-Bourgade S, Radal M, Penault-Llorca F, et al. Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray. Virchows Arch. 2006;449:281\u20137.","journal-title":"Virchows Arch"},{"key":"691_CR23","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","volume":"26","author":"J Jassem","year":"2008","unstructured":"Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008;26:1698\u2013704.","journal-title":"J Clin Oncol"},{"key":"691_CR24","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960\u20136.","journal-title":"J Clin Oncol"},{"key":"691_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303\u201312.","journal-title":"Lancet"},{"key":"691_CR26","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909\u201319.","journal-title":"N Engl J Med"},{"key":"691_CR27","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/00001622-200111000-00014","volume":"13","author":"ES Kim","year":"2001","unstructured":"Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol. 2001;13:506\u201313.","journal-title":"Curr Opin Oncol"},{"key":"691_CR28","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, Von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065\u201375.","journal-title":"Lancet Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-019-00691-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-019-00691-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-019-00691-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T19:55:30Z","timestamp":1607370930000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-019-00691-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,9]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["691"],"URL":"https:\/\/doi.org\/10.1007\/s11523-019-00691-z","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,9]]},"assertion":[{"value":"9 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Seung Tae Kim, Jung Yong Hong, Jeeyun Lee, Joon Oh Park, Ho Young Lim, Won Ki Kang, and Young Suk Park declare that they have no conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}